Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study.

Sami Diab,Hope S. Rugo,Lida A. Mina,Shannon Puhalla,Reshma L. Mahtani,Norah Lynn Henry,Neelima Denduluri,Denise A. Yardley,Yao Wang,Lillian Shahied Arruda,Iulia Cristina Tudor,Eric Gauthier,Akos Czibere,Jennifer K. Litton,Sara A. Hurvitz

Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study.

2019

Sami Diab
Hope S. Rugo
Lida A. Mina
Shannon Puhalla
Reshma L. Mahtani
Norah Lynn Henry
Neelima Denduluri
Denise A. Yardley
Yao Wang
Lillian Shahied Arruda
Iulia Cristina Tudor
Eric Gauthier
Akos Czibere
Jennifer K. Litton
Sara A. Hurvitz

1044Background: TALA is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the US for HER2- gBRCAm LA/MBC. Approval was based on results from the Phase 3 EMBRACA trial comparing efficacy/sa...

Keywords:

Polymerase
Germline
Pathology
Oncology
Talazoparib
Metastatic breast cancer
Internal medicine
Medicine
locally advanced

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations